The genetic program of the human T cell is a complex one which includes both immunoregulation as well as the capacity to recognize specific antigens and execute unique effector programs. One of the consequences of T cell recognition by allo-MHC is the generation of both specific cytotoxic T lymphocytes and inflammatory responses high can result in graft rejection. T cell activation and proliferation are initiated through interactions of the T cell receptor complex with accessory cells crosslinking the TCR with the natural ligand, for example, allo-MHC or mimicked by antibodies directed at the TCR or its noncovalently associated T3 molecules. Crosslinking of the TCR is markably enhanced by the associative recognition structures, T4 and T8. Under physiologic conditions, a quaternary structure involving T3/TCR, T4, T8 and class I and class II MHC structures is generated which leads to T cell activation and the associated MHC restrictions. T cell help results from the activation of the T4+4B4+ network and suppression by the activation of the T4+2H4+ network. Some antibodies directed at the T4, T8 and T3 structures have been shown to be immunosuppressive. The mechanism by which anti-T cell antibodies result in suppression is of major importance for the treatment of patients undergoing renal graft rejection. Antibodies used therapeutically have been selected for their ability to facilitate target cell depletion rather than their """"""""independent immunosuppressive effects"""""""". The purpose of this proposal to generate antibodies with therapeutic ability whose major virtue is their capacity to either modulate the host immune response or prevent activation of the cellular immune response. We plan to develop antibodies which can block the association of the T3/TCR complex and relevant accessory molecules such as T4, T8, and Tll. Since this association represents a potent branch point for T cell activation, we believe that blocking this interaction should facilitate the abrogation of T cell mediated renal graft rejection. In addition, we will prepare new antibodies capable of directly enhancing the induction of suppression or by the blocking of the induction of help. The helper circuit is necessary for the activation of an antibody production and the generation of cytotoxic T cells. Lastly, we will develop antibodies specific for cytotoxic effector T cells which spare the suppressor pathway.

Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Duke-Cohan, J S; Morimoto, C; Rocker, J A et al. (1996) Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 156:1714-21
Duke-Cohan, J S; Morimoto, C; Rocker, J A et al. (1995) A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 270:14107-14
Martin-Reay, D G; Kamentsky, L A; Weinberg, D S et al. (1994) Evaluation of a new slide-based laser scanning cytometer for DNA analysis of tumors. Comparison with flow cytometry and image analysis. Am J Clin Pathol 102:432-8
Dawson, A E; Cibas, E S; Bacus, J W et al. (1993) Chromatin texture measurement by Markovian analysis. Use of nuclear models to define and select texture features. Anal Quant Cytol Histol 15:227-35
Araten, D J; Lawton, T; Ferrara, J et al. (1993) In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance. Transplantation 55:76-82
Sayegh, M H; Khoury, S J; Hancock, W W et al. (1993) Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc 25:357-8
Weinberg, D S; Weidner, N (1993) Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. Arch Pathol Lab Med 117:1132-7
Duke-Cohan, J S; Morimoto, C; Schlossman, S F (1993) Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood 82:2224-34
Duke-Cohan, J S; Morimoto, C; Schlossman, S F (1993) Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Transplantation 56:1188-96
Hancock, W W; Sayegh, M H; Kwok, C A et al. (1993) Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 55:1112-8

Showing the most recent 10 out of 30 publications